<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS200375</article-id><article-id pub-id-type="doi">10.1101/2024.11.16.623971</article-id><article-id pub-id-type="archive">PPR942656</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Reduced prevalence of phage defense systems in <italic>Pseudomonas aeruginosa</italic> strains from Cystic Fibrosis Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van den Berg</surname><given-names>Daan F.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brouns</surname><given-names>Stan J.J.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Bionanoscience, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02e2c7k09</institution-id><institution>Delft University of Technology</institution></institution-wrap>, <postal-code>2629</postal-code> HZ <city>Delft</city>, <country country="NL">Netherlands</country></aff><aff id="A2"><label>2</label>Kavli Institute of Nanoscience, Delft, Netherlands</aff><author-notes><corresp id="CR1">
<label>*</label>Correspondence: <email>stanbrouns@gmail.com</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>21</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>19</day><month>11</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Cystic fibrosis is a genetic disorder that affects mucus clearance, particularly of the lungs. As a result, cystic fibrosis patients often experience infections from bacteria, which contribute to the disease progression. <italic>Pseudomonas aeruginosa</italic> is one of the most common opportunistic pathogens associated with cystic fibrosis. The presence of <italic>P. aeruginosa</italic> complicates the treatment due to its high antibiotic resistance. Thus, research is ongoing to treat these infections with bacterial viruses instead, known as bacteriophages. Notably, <italic>P. aeruginosa</italic> clinical strains possess a variety of phage defense mechanisms that may limit the effectiveness of phage therapy. In this study, we compared the defense system repertoire of <italic>P. aeruginosa</italic> strains isolated from cystic fibrosis patients with those from non-cystic fibrosis patients. Our findings reveal that <italic>P. aeruginosa</italic> strains isolated from cystic fibrosis patients have fewer phage defense mechanisms per strain than from non-cystic fibrosis patients, suggesting altered phage selection pressures in strains colonizing CF patient lungs.</p></abstract><kwd-group><kwd>Phage defense systems</kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd><kwd>cystic fibrosis</kwd><kwd>phage therapy</kwd><kwd>mucus</kwd><kwd>Zorya</kwd><kwd>CRISPR-Cas</kwd><kwd>Wadjet</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Cystic fibrosis (CF) is a genetic disorder that affects mucus clearance, especially of the lungs<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. The decrease in mucus clearance creates a breeding ground for opportunistic pathogens, such as bacteria, to colonize the lungs<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. These infections are often chronic, accumulate resistance to antibiotic treatment, and cause major lung damage<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup>. Over time, this damage results in respiratory failure, the most common cause of death for CF patients<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. Lung infections in CF patients are often caused by strains of <italic>Pseudomonas aeruginosa</italic><sup><xref ref-type="bibr" rid="R1">1</xref></sup>. Although antibiotic treatments can alleviate patient symptoms and prolong life, they generally fail to fully eradicate <italic>P. aeruginosa</italic> from the lungs<sup><xref ref-type="bibr" rid="R3">3</xref></sup>. Consequently, research has turned to alternative treatment options, including the use of bacterial viruses (phages)<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup>. However, the efficacy of phage-based treatments might also be limited since <italic>P. aeruginosa</italic> strains often possess a variety of phage defense mechanisms that may limit the sensitivity of strains to phages<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. Particularly, a recent study on the abundance of defense systems in clinical isolates of <italic>P. aeruginosa</italic> found that these strains accumulate a large number of defense systems and are less susceptible to phage infection<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. However, it is unknown if the distribution of phage defense systems varies with the pathogen environment or patient conditions. In this study, we investigated the defense system repertoire of clinical <italic>P. aeruginosa</italic> isolates from mucus-rich lungs of CF patients by comparing them to strains isolated from non-CF lung patients.</p></sec><sec id="S2" sec-type="results | discussion"><title>Results and discussion</title><p id="P3">We utilized the Pseudomonas Genome Database to investigate the defense system repertoire of <italic>P. aeruginosa</italic> isolates from the respiratory system of CF and non-CF (e.g. pneumonia) patients<sup><xref ref-type="bibr" rid="R10">10</xref></sup>. We first compared the prevalence of the phage defense systems and found isolates from CF patients to encode significantly fewer phage defense systems per strain (non-CF: 9.8 vs CF: 6.8; a 30% reduction; Welch Two Sample t-test, t = -9.878, df = 601.37, p-value &lt; 2.2<sup>-16</sup>) (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Interestingly, this reduction in the number of defense systems per strain did not affect the overall diversity of the defense repertoire, where the Shannon index (Both: 3.86) and evenness (Both: 0.80) remained identical (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Therefore, we hypothesized that the decrease in defense systems per strain is not the result of a broad, non-specific reduction. Instead, we suspected that the overall reduction is possibly caused by differences in the abundance of a few prevalent defense systems. To assess this, we compared the abundance of each defense system in CF vs non-CF lung isolates (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>), considering changes greater than 2-fold (log<sub>2</sub>FC &gt; 1 or log<sub>2</sub>FC &lt; -1) as relevant (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). We identified 31 defense systems with considerable changes in abundance (seven were more abundant and 24 were less abundant in CF strains; <xref ref-type="fig" rid="F1">Figure 1B-C</xref>, <xref ref-type="supplementary-material" rid="SD1">SC-E</xref>), but only four of these systems were prevalent enough to potentially affect the overall number of defense systems per strain (present in more than 10%) in either group, all four were more depleted in CF isolates. These four defense systems include Wadjet type I<sup><xref ref-type="bibr" rid="R11">11</xref></sup> (non-CF: 37.8% vs CF:13.4%; log<sub>2</sub>FC = -1.4), Shedu<sup><xref ref-type="bibr" rid="R12">12</xref></sup> (non-CF: 23.5% vs CF: 9.7%; log<sub>2</sub>FC = -1.2), RM type III (non-CF: 23.5% vs CF: 7.7%; log<sub>2</sub>FC = -1.5) and Zorya type I<sup><xref ref-type="bibr" rid="R13">13</xref></sup> (non-CF: 24.4% vs CF: 3.4%; log<sub>2</sub>FC = -2.5). The reduced prevalence of just these four defense systems accounts for almost half the reduction in defense system number per strain observed in CF compared to non-CF isolates. Besides these defense systems, CRISPR-Cas type IV-A is also noteworthy for being completely absent in the CF isolates, while present in the non-CF isolates (non-CF: 2.6% vs CF: 0%; log<sub>2</sub>FC = -1.8). Interestingly, all of the above-mentioned defense systems act on foreign DNA, and notably, two of these defense systems, Wadjet type I and CRISPR-Cas type IV-A, are known to act upon plasmids specifically<sup><xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup>. The reduced presence of plasmid-restrictive mechanisms of these strains may highlight the role of plasmids in CF-infecting strains, potentially facilitating their acquisition to gain resistance against antibiotics used for treating CF infections<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>.</p><p id="P4">It remains unclear whether the reduced prevalence of defense systems in CF isolates was caused by strain selection before, or during lung infection in CF patients. As for antibiotic resistance, strains infecting CF lungs adapt over time<sup><xref ref-type="bibr" rid="R1">1</xref></sup>, and could therefore also adapt in the context of phages and other mobile genetic elements such as plasmids. In the CF lung environment, this adaptation seems to involve the loss of phage defense mechanisms, possibly because CF lungs are less penetrable to phages due to factors such as reduced air circulation, a thicker and dehydrated mucus layer, and a higher prevalence of biofilms<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R18">18</xref></sup>. Supporting this hypothesis, we observed fewer prophages in the genomes of CF lung isolates, suggesting reduced exposure to phage predation (CF: 3.3 vs non-CF: 5.3 prophages per genome; 38% decrease; Welch Two Sample t-test: t = -12.379, df = 508.88, p-value &lt; 2.2<sup>-16</sup>) (<xref ref-type="supplementary-material" rid="SD1">Figure S1F</xref>). Besides the reduced phage defenses of <italic>P. aeruginosa</italic> isolates from CF lung isolates we also observed these strains to have a significantly smaller genome (CF: 6.5 Mb vs non-CF: 6.8 Mb; a 4% decrease; Welch Two Sample t-test: t = -13.811, df = 594.47, p-value &lt; 2.2<sup>-16</sup>) and to encode fewer genes (CF: 6053 vs non-CF: 6298 genes; a 4% decrease; Welch Two Sample t-test: t = -11.715, df = 625.07, p-value &lt; 2.2<sup>-16</sup>) (<xref ref-type="supplementary-material" rid="SD1">Figure S1G,H</xref>). These characteristics reflect a more adapted and specialized genome of <italic>Pseudomonas aeruginosa</italic> strains in the CF lung environment<sup><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>.</p></sec><sec id="S3" sec-type="conclusions"><title>Conclusion</title><p id="P5">We observed that <italic>P. aeruginosa</italic> strains isolated from the lungs of CF patients encode a more limited number of phage defense systems compared to strains isolated from non-CF patient lungs. This can largely be attributed to a reduced abundance of several key phage defense systems including Wadjet, Shedu, Zorya, and RM type, which likely results from adaptation to the CF lung environment. This provides a promising perspective that these bacterial strains are more susceptible to phage therapeutic options.</p></sec><sec id="S4" sec-type="methods"><title>Method</title><p id="P6">All complete <italic>P. aeruginosa</italic> genomes were downloaded from the Pseudomonas Genome Database on the 9th of April 2023 (n = 14,230). The metadata was utilized to select the strains for: Species = <italic>Pseudomonas aeruginosa</italic>, Assembly version status = latest, Host taxonomic name = Homo sapiens. A further selection was then made between isolates from the respiratory system of CF (n = 602) and those of non-CF (n = 348) (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). The non-CF patients primarily were affected by unspecified respiratory tract infection (57.5%), ventilator-associated pneumonia (20.1%), and pneumonia (12.4%). Chronic bronchitis and chronic obstructive pulmonary disease were less frequently prevalent, 4.9% and 0.3% respectively. Defense systems were detected in <italic>P. aeruginosa</italic> genomes with DefenseFinder v1.3.0<sup><xref ref-type="bibr" rid="R22">22</xref></sup> using DefenseFinderModels v1.3.0. Prophages were identified using PhiSpy v4.2.21 (default settings)<sup><xref ref-type="bibr" rid="R23">23</xref></sup>.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS200375-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d46aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S5"><title>Acknowledgments</title><p>We thank members of the Brounslab for the many discussions and ideas that improved our work. Especially, dr. Nadiia Pozhydaieva and dr. Ana Rita Costa for critically reading and providing feedback on the manuscript.</p><sec id="S6"><title>Funding</title><p>This work was supported by the European Research Council (ERC) CoG grant no. 10100322 to S.J.J.B.</p></sec></ack><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>D</given-names><suffix>Jr</suffix></name><name><surname>Wozniak</surname><given-names>DJ</given-names></name></person-group><article-title>Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface</article-title><source>Clinical microbiology reviews</source><year>2019</year><volume>32</volume><issue>3</issue><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="pmcid">PMC6589863</pub-id><pub-id pub-id-type="pmid">31142499</pub-id><pub-id pub-id-type="doi">10.1128/CMR.00138-18</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonyadi</surname><given-names>P</given-names></name><name><surname>Saleh</surname><given-names>NT</given-names></name><name><surname>Dehghani</surname><given-names>M</given-names></name><name><surname>Yamini</surname><given-names>M</given-names></name><name><surname>Amini</surname><given-names>K</given-names></name></person-group><article-title>Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis</article-title><source>Microbial Pathogenesis</source><year>2022</year><volume>165</volume><elocation-id>105461</elocation-id><pub-id pub-id-type="pmid">35240288</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>L</given-names></name><name><surname>Waters</surname><given-names>V</given-names></name></person-group><article-title>Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis</article-title><source>J Cyst Fibros</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">33172756</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cafora</surname><given-names>M</given-names></name><name><surname>Deflorian</surname><given-names>G</given-names></name><name><surname>Forti</surname><given-names>F</given-names></name><name><surname>Ferrari</surname><given-names>L</given-names></name><name><surname>Binelli</surname><given-names>G</given-names></name><name><surname>Briani</surname><given-names>F</given-names></name><etal/><name><surname>Pistocchi</surname><given-names>A</given-names></name></person-group><article-title>Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model</article-title><source>Scientific reports</source><year>2019</year><volume>9</volume><issue>1</issue><elocation-id>1527</elocation-id><pub-id pub-id-type="pmcid">PMC6365511</pub-id><pub-id pub-id-type="pmid">30728389</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-37636-x</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>A</given-names></name><name><surname>Sami</surname><given-names>I</given-names></name><name><surname>Chaney</surname><given-names>H</given-names></name><name><surname>Koumbourlis</surname><given-names>AC</given-names></name><name><surname>Del Valle Mojica</surname><given-names>C</given-names></name><name><surname>Cochrane</surname><given-names>C</given-names></name><etal/><name><surname>Koff</surname><given-names>JL</given-names></name></person-group><article-title>Bacteriophage therapy for pan-drug-resistant Pseudomonas aeruginosa in two persons with cystic fibrosis</article-title><source>Journal of Investigative Medicine High Impact Case Reports</source><year>2023</year><volume>11</volume><elocation-id>23247096231188243</elocation-id><pub-id pub-id-type="pmcid">PMC10387758</pub-id><pub-id pub-id-type="pmid">37515541</pub-id><pub-id pub-id-type="doi">10.1177/23247096231188243</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Yeoh</surname><given-names>E</given-names></name><name><surname>Fitzgerald</surname><given-names>DA</given-names></name><name><surname>Selvadurai</surname><given-names>H</given-names></name></person-group><article-title>A systematic review on the use of bacteriophage in treating Staphylococcus aureus and Pseudomonas aeruginosa infections in cystic fibrosis</article-title><source>Paediatric Respiratory Reviews</source><year>2023</year><pub-id pub-id-type="pmid">37598024</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernabéu-Gimeno</surname><given-names>M</given-names></name><name><surname>Pardo-Freire</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>BK</given-names></name><name><surname>Turner</surname><given-names>PE</given-names></name><name><surname>Gil-Brusola</surname><given-names>A</given-names></name><name><surname>Pérez-Tarazona</surname><given-names>S</given-names></name><etal/><name><surname>Domingo-Calap</surname><given-names>P</given-names></name></person-group><article-title>Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients</article-title><source>Med</source><year>2024</year><volume>5</volume><issue>9</issue><fpage>1096</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">38917792</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirnay</surname><given-names>JP</given-names></name><name><surname>Djebara</surname><given-names>S</given-names></name><name><surname>Steurs</surname><given-names>G</given-names></name><name><surname>Griselain</surname><given-names>J</given-names></name><name><surname>Cochez</surname><given-names>C</given-names></name><name><surname>De Soir</surname><given-names>S</given-names></name><etal/><name><surname>Merabishvili</surname><given-names>M</given-names></name></person-group><article-title>Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study</article-title><source>Nature Microbiology</source><year>2024</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC11153159</pub-id><pub-id pub-id-type="pmid">38834776</pub-id><pub-id pub-id-type="doi">10.1038/s41564-024-01705-x</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>AR</given-names></name><name><surname>van den Berg</surname><given-names>DF</given-names></name><name><surname>Esser</surname><given-names>JQ</given-names></name><name><surname>Muralidharan</surname><given-names>A</given-names></name><name><surname>van den Bossche</surname><given-names>H</given-names></name><name><surname>Bonilla</surname><given-names>BE</given-names></name><etal/><name><surname>Brouns</surname><given-names>SJ</given-names></name></person-group><article-title>Accumulation of defense systems in phage-resistant strains of Pseudomonas aeruginosa</article-title><source>Science Advances</source><year>2024</year><volume>10</volume><issue>8</issue><elocation-id>eadj0341</elocation-id><pub-id pub-id-type="pmcid">PMC10889362</pub-id><pub-id pub-id-type="pmid">38394193</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.adj0341</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winsor</surname><given-names>GL</given-names></name><name><surname>Lam</surname><given-names>DK</given-names></name><name><surname>Fleming</surname><given-names>L</given-names></name><name><surname>Lo</surname><given-names>R</given-names></name><name><surname>Whiteside</surname><given-names>MD</given-names></name><name><surname>Yu</surname><given-names>NY</given-names></name><etal/><name><surname>Brinkman</surname><given-names>FS</given-names></name></person-group><article-title>Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes</article-title><source>Nucleic acids research</source><year>2010</year><volume>39</volume><issue>suppl_1</issue><fpage>D596</fpage><lpage>D600</lpage><pub-id pub-id-type="pmcid">PMC3013766</pub-id><pub-id pub-id-type="pmid">20929876</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkq869</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deep</surname><given-names>A</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>YQ</given-names></name><name><surname>Ego</surname><given-names>KM</given-names></name><name><surname>Herzik</surname><given-names>MA</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Corbett</surname><given-names>KD</given-names></name></person-group><article-title>The SMC-family Wadjet complex protects bacteria from plasmid transformation by recognition and cleavage of closed-circular DNA</article-title><source>Molecular Cell</source><year>2022</year><volume>82</volume><issue>21</issue><fpage>4145</fpage><lpage>4159</lpage><pub-id pub-id-type="pmcid">PMC9637719</pub-id><pub-id pub-id-type="pmid">36206765</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2022.09.008</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeff</surname><given-names>L</given-names></name><name><surname>Walter</surname><given-names>A</given-names></name><name><surname>Rosalen</surname><given-names>GT</given-names></name><name><surname>Jinek</surname><given-names>M</given-names></name></person-group><article-title>DNA end sensing and cleavage by the Shedu anti-phage defense system</article-title><source>bioRxiv</source><year>2023</year><fpage>2023</fpage><lpage>08</lpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Hughes</surname><given-names>TC</given-names></name><name><surname>Popp</surname><given-names>PF</given-names></name><name><surname>Roa-Eguiara</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Rutbeek</surname><given-names>NR</given-names></name><etal/><name><surname>Taylor</surname><given-names>NM</given-names></name></person-group><article-title>Structure and mechanism of Zorya anti-phage defense system</article-title><source>bioRxiv</source><year>2023</year><fpage>2023</fpage><lpage>12</lpage></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doron</surname><given-names>S</given-names></name><name><surname>Melamed</surname><given-names>S</given-names></name><name><surname>Ofir</surname><given-names>G</given-names></name><name><surname>Leavitt</surname><given-names>A</given-names></name><name><surname>Lopatina</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>M</given-names></name><etal/><name><surname>Sorek</surname><given-names>R</given-names></name></person-group><article-title>Systematic discovery of antiphage defense systems in the microbial pangenome</article-title><source>Science</source><year>2018</year><volume>359</volume><issue>6379</issue><elocation-id>eaar4120</elocation-id><pub-id pub-id-type="pmcid">PMC6387622</pub-id><pub-id pub-id-type="pmid">29371424</pub-id><pub-id pub-id-type="doi">10.1126/science.aar4120</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinilla-Redondo</surname><given-names>R</given-names></name><name><surname>Mayo-Muñoz</surname><given-names>D</given-names></name><name><surname>Russel</surname><given-names>J</given-names></name><name><surname>Garrett</surname><given-names>RA</given-names></name><name><surname>Randau</surname><given-names>L</given-names></name><name><surname>Sørensen</surname><given-names>SJ</given-names></name><name><surname>Shah</surname><given-names>SA</given-names></name></person-group><article-title>Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids</article-title><source>Nucleic acids research</source><year>2020</year><volume>48</volume><issue>4</issue><fpage>2000</fpage><lpage>2012</lpage><pub-id pub-id-type="pmcid">PMC7038947</pub-id><pub-id pub-id-type="pmid">31879772</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz1197</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SL</given-names></name><name><surname>Leong</surname><given-names>LE</given-names></name><name><surname>Sims</surname><given-names>SK</given-names></name><name><surname>Keating</surname><given-names>RL</given-names></name><name><surname>Papanicolas</surname><given-names>LE</given-names></name><name><surname>Richard</surname><given-names>A</given-names></name><etal/><name><surname>Rogers</surname><given-names>GB</given-names></name></person-group><article-title>The cystic fibrosis gut as a potential source of multidrug resistant pathogens</article-title><source>Journal of Cystic Fibrosis</source><year>2021</year><volume>20</volume><issue>3</issue><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">33250435</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castañeda-Barba</surname><given-names>S</given-names></name><name><surname>Top</surname><given-names>EM</given-names></name><name><surname>Stalder</surname><given-names>T</given-names></name></person-group><article-title>Plasmids, a molecular cornerstone of antimicrobial resistance in the One Health era</article-title><source>Nature Reviews Microbiology</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>18</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">37430173</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>KM</given-names></name><name><surname>Stick</surname><given-names>SM</given-names></name><name><surname>Kicic</surname><given-names>A</given-names></name></person-group><article-title>Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?</article-title><source>Frontiers in Medicine</source><year>2023</year><volume>10</volume><elocation-id>1088494</elocation-id><pub-id pub-id-type="pmcid">PMC10230084</pub-id><pub-id pub-id-type="pmid">37265479</pub-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1088494</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentkowski</surname><given-names>P</given-names></name><name><surname>Van Oosterhout</surname><given-names>C</given-names></name><name><surname>Mock</surname><given-names>T</given-names></name></person-group><article-title>A model of genome size evolution for prokaryotes in stable and fluctuating environments</article-title><source>Genome biology and evolution</source><year>2015</year><volume>7</volume><issue>8</issue><fpage>2344</fpage><lpage>2351</lpage><pub-id pub-id-type="pmcid">PMC4558865</pub-id><pub-id pub-id-type="pmid">26242601</pub-id><pub-id pub-id-type="doi">10.1093/gbe/evv148</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merhej</surname><given-names>V</given-names></name><name><surname>Royer-Carenzi</surname><given-names>M</given-names></name><name><surname>Pontarotti</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>Massive comparative genomic analysis reveals convergent evolution of specialized bacteria</article-title><source>Biology direct</source><year>2009</year><volume>4</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="pmcid">PMC2688493</pub-id><pub-id pub-id-type="pmid">19361336</pub-id><pub-id pub-id-type="doi">10.1186/1745-6150-4-13</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>E</given-names></name><name><surname>La Rosa</surname><given-names>R</given-names></name><name><surname>Bartell</surname><given-names>JA</given-names></name><name><surname>Marvig</surname><given-names>RL</given-names></name><name><surname>Haagensen</surname><given-names>JA</given-names></name><name><surname>Sommer</surname><given-names>LM</given-names></name><etal/><name><surname>Johansen</surname><given-names>HK</given-names></name></person-group><article-title>Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis</article-title><source>Nature Reviews Microbiology</source><year>2021</year><volume>19</volume><issue>5</issue><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">33214718</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesson</surname><given-names>F</given-names></name><name><surname>Planel</surname><given-names>R</given-names></name><name><surname>Egorov</surname><given-names>AA</given-names></name><name><surname>Georjon</surname><given-names>H</given-names></name><name><surname>Vaysset</surname><given-names>H</given-names></name><name><surname>Brancotte</surname><given-names>B</given-names></name><etal/><name><surname>Cury</surname><given-names>J</given-names></name></person-group><article-title>A comprehensive resource for exploring antiphage defense: DefenseFinder Webservice, Wiki and Databases</article-title><source>Peer Community Journal</source><year>2024</year><volume>4</volume></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhter</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>RK</given-names></name><name><surname>Edwards</surname><given-names>RA</given-names></name></person-group><article-title>PhiSpy: a novel algorithm for finding prophages in bacterial genomes that combines similarity-and composition-based strategies</article-title><source>Nucleic acids research</source><year>2012</year><volume>40</volume><issue>16</issue><fpage>e126</fpage><pub-id pub-id-type="pmcid">PMC3439882</pub-id><pub-id pub-id-type="pmid">22584627</pub-id><pub-id pub-id-type="doi">10.1093/nar/gks406</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Importance</title></caption><p>Cystic fibrosis patients often experience chronic <italic>Pseudomonas aeruginosa</italic> lung infections, which are challenging to treat with antibiotics and contribute to disease progression and eventual respiratory failure. Phage therapy is being explored as an alternative treatment strategy for these infections. However, assessing strain susceptibility to phage treatment is essential for ensuring efficacy. To address this, we investigated whether CF-associated clinical <italic>P. aeruginosa</italic> strains have a distinct phage defense repertoire compared to those isolated from other lung patients. We observed that CF-associated <italic>P. aeruginosa</italic> strains have significantly fewer phage defenses, possibly affecting the susceptibility of these strains to phage infection.</p></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title><italic>Pseudomonas aeruginosa</italic> strains isolated from cystic fibrosis (CF) patient lungs have fewer defense systems.</title><p>(A) The number of defense systems per <italic>P. aeruginosa</italic> strain isolated from CF lungs (left) and non-CF lungs (right). The median number of defense systems per strain is indicated with a lighter red colored bar. (B) The comparative abundance of individual defense systems in <italic>P. aeruginosa</italic> strains isolated from CF and non-CF lungs. The graph is divided into four sections: Red represents a log<sub>2</sub>FC greater than 1, light red indicates a log<sub>2</sub>FC between 0 and 1, light blue corresponds to a log<sub>2</sub>FC between 0 and -1, and blue signifies a log<sub>2</sub>FC less than -1. (C) The relative log<sub>2</sub>FC change in the prevalence of individual defense systems in <italic>P. aeruginosa</italic> strains isolated from CF lungs compared to non-CF lungs. A larger depiction of this graph, which also shows the individual defense system names, can be seen in <xref ref-type="supplementary-material" rid="SD1">supplementary figure S1C</xref>.</p></caption><graphic xlink:href="EMS200375-f001"/></fig></floats-group></article>